Document Detail

Inhaled corticosteroids in COPD: determinants of use and trends in patient persistence with treatment.
MedLine Citation:
PMID:  15010729     Owner:  NLM     Status:  MEDLINE    
METHODS: The determinants of a new treatment with inhaled corticosteroids and secular trends in patient persistence with treatment among chronic obstructive pulmonary disease (COPD) patients were investigated. A cohort of 3768 physician-diagnosed, elderly COPD patients was selected between 1990 and 1996 from the health care administrative database of the Régie de l'assurance maladie du Québec. A nested case-control design was used to identify patient and physician characteristics that were associated with a new treatment with inhaled corticosteroids. Treatment persistence with inhaled corticosteroids was also estimated using Kaplan-Meier analysis. In addition to that, changes in treatment persistence over time, from 1990 to 1995, were investigated by estimating the yearly proportion of patients persisting for less than one year. RESULTS: Within the cohort, the yearly percentage of patients filling at least one prescription for inhaled corticosteroids was 42.2% in 1990 and increased to 53.1% in 1995 (P=0.001). Using a conditional logistic regression model, it was found that the patients most likely to initiate a treatment with inhaled corticosteroids were those who had severe COPD (rate ratio [RR] 1.7; 95% CI 1.4 to 2.0), those who were hospitalized for COPD (RR 10.0; 95% CI 5.6 to 17.9), those who consulted a respirologist in the previous month (RR 2.3; 95% CI 1.6 to 3.3) or those who visited more than three different physicians in the previous three months (RR 1.6; 95% Cl 1.3 to 1.9). The proportion of patients persisting with inhaled corticosteroids for less than one year rose by 19.4%, from 47.6% in 1990 to 67.0% in 1995 (P=0.011; test for trend). CONCLUSIONS: The use of inhaled corticosteroids increased while patient persistence decreased between 1990 and 1995. Disease severity, as well as recent consultation to a respirologist and multiple visits to a physician, were associated with a strong likelihood of being prescribed inhaled corticosteroids. The cost of this practice is far from negligible, while their clinical impact is still uncertain.
Lucie Blais; Jean Bourbeau; Odile Sheehy; Jacques LeLorier
Related Documents :
21825849 - Thyroid remnant estimation by tc-99m-sestamibi scanning predicts the effectiveness of r...
7744199 - Does phase 2 of the expiratory pco2 versus volume curve have diagnostic value in emphys...
9930599 - Sensory hyperreactivity--a possible mechanism underlying cough and asthma-like symptoms.
11941309 - Exhaled leukotrienes and prostaglandins in asthma.
2551599 - Face-mask cpap and sodium bicarbonate infusion in acute, severe asthma and metabolic ac...
7824809 - Efficacy and tolerance of a 12-week treatment with inhaled formoterol in patients with ...
8976639 - Staphylococcus aureus nasal carriage in rheumatoid arthritis: antibody response to toxi...
3780609 - Prevalence and prognosis of epilepsy in patients with multiple sclerosis.
23185799 - Correlation of human papilloma virus infection with cytology, colposcopy and histopatho...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Canadian respiratory journal : journal of the Canadian Thoracic Society     Volume:  11     ISSN:  1198-2241     ISO Abbreviation:  Can. Respir. J.     Publication Date:    2004 Jan-Feb
Date Detail:
Created Date:  2004-03-10     Completed Date:  2004-08-09     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9433332     Medline TA:  Can Respir J     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  27-32     Citation Subset:  IM    
Centre de recherche, Centre hospitalier de l'Université de Montréal-Hôtel Dieu, Montreal, Quebec.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Inhalation
Adrenal Cortex Hormones / administration & dosage*
Case-Control Studies
Cohort Studies
Outcome and Process Assessment (Health Care)
Patient Compliance / statistics & numerical data*
Pulmonary Disease, Chronic Obstructive / drug therapy*
Quebec / epidemiology
Reg. No./Substance:
0/Adrenal Cortex Hormones
Comment In:
Can Respir J. 2004 Jan-Feb;11(1):13-4   [PMID:  15010726 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Zafirlukast (Accolate).
Next Document:  Different profile of interleukin-10 production in circulating T cells from atopic asthmatics compare...